Alemtuzumab: Completed Phase III enrollment

Genzyme completed enrollment of 845 treatment-experienced relapsing-remitting MS patients in the 2-year, single-blind, international Phase III CARE-MS II trial. The study is evaluating 12 or 24 mg IV ...